Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MacroTrans: Radiotherapy and Immunotherapy for HCC Downstaging
NCT06725121Phase 2Recruiting
- Sponsor
- University Health Network
- Start
- Dec 2024
- Primary completion
- Jun 2031
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab, bevacizumab in hepatocellular carcinoma (HCC), sponsored by University Health Network. Started Dec 2024; status: recruiting.
02
Drugs
atezolizumabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06725121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06725121.